Company Profile

Company Description

Cara Therapeutics, Inc. is a biopharmaceutical firm focused on developing and commercializing innovative therapeutics to alleviate pruritus (itching) by selectively targeting peripheral kappa opioid receptors. The company's lead product candidate, KORSUVA, is designed to treat chronic kidney disease-associated pruritus and other conditions. Their research aims to provide non-addictive, effective treatments for patients suffering from moderate-to-severe itch, addressing unmet medical needs. By leveraging novel mechanisms of action, the company strives to improve quality of life for individuals with chronic pruritus while minimizing systemic side effects. Their pipeline includes both injectable and oral formulations targeting various itch-related disorders.